Trial Search Results

In Vivo Characterization of Macrophages in Pediatric Patients With Malignant Brain Tumors Using Ferumoxytol-enhanced MRI

This pilot early phase I trial studies how well ferumoxytol-enhanced magnetic resonance imaging (MRI) correlates with inflammatory (macrophage) responses in pediatric patients with malignant brain tumors. If there is good correlation, ferumoxytol-enhanced MRI can serve as a noninvasive imaging biomarker of inflammation.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Michael Iv

Collaborator: National Cancer Institute (NCI)


  • Diagnostic Test: Diagnostic (ferumoxytol-enhanced MRI)
  • Procedure: Surgery
  • Drug: Ferumoxytol
  • Other: Tissue Analysis


Early Phase 1


Inclusion Criteria:

   - Any patient with suspected malignant brain tumor on diagnostic MR imaging who will
   undergo a resection

Exclusion Criteria:

   - Informed consent cannot be obtained either from the patient or legal representative

   - Severe coexisting or terminal systemic disease that may interfere with the conduct of
   the study

   - Contraindication to MRI (metal implants)

   - Hemosiderosis/hemochromatosis

   - Iron overload from any cause (not just hemosiderosis or hemochromatosis), even if
   secondary to frequent blood transfusions, severe chronic hemolysis, excess dietary or
   parenteral iron, or any other etiology

   - Known hypersensitivity to ferumoxytol or any of its components

   - Pregnant patients

Ages Eligible for Study

2 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Paymon Rezaii